KR101012917B1 - 피롤 헵탄산 화합물의 신규한 결정형 - Google Patents
피롤 헵탄산 화합물의 신규한 결정형 Download PDFInfo
- Publication number
- KR101012917B1 KR101012917B1 KR1020080019764A KR20080019764A KR101012917B1 KR 101012917 B1 KR101012917 B1 KR 101012917B1 KR 1020080019764 A KR1020080019764 A KR 1020080019764A KR 20080019764 A KR20080019764 A KR 20080019764A KR 101012917 B1 KR101012917 B1 KR 101012917B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- alcohol
- hydrate
- present
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Abstract
Description
2θ | d(Å) | 상대강도 (>10%) |
5.36 | 16.4745 | 13.4 |
7.38 | 11.9689 | 17.0 |
7.68 | 11.5022 | 29.6 |
8.14 | 10.8531 | 31.7 |
8.60 | 10.2733 | 68.6 |
8.88 | 9.9503 | 30.4 |
10.24 | 8.6312 | 45.3 |
12.48 | 7.0867 | 19.7 |
13.80 | 6.4115 | 12.7 |
17.14 | 5.1691 | 14.5 |
17.78 | 4.9844 | 45.3 |
18.22 | 4.8651 | 12.8 |
18.52 | 4.7870 | 10.1 |
19.36 | 4.5811 | 100 |
19.96 | 4.4447 | 13.0 |
20.76 | 4.2752 | 45.1 |
22.40 | 3.9658 | 17.9 |
23.20 | 3.8307 | 12.6 |
24.18 | 3.6777 | 11.5 |
25.62 | 3.4742 | 14.1 |
탄소의 지정 | 화학적 이동 |
C12 또는 C25 | 179.6 |
C12 또는 C25 | 169.1 |
C16 | 162.5 |
방향족 탄소 C2-C5, C13-C18, C19-C24, C27-C32 |
140.0, 138.0, 133.8, 131.9, 129.6, 126.0, 119.2, 114.7 |
C8, C10 | 73.6, 71.2, 69.9 |
메틸렌 탄소 C6, C7, C9, C11 |
48.0, 45.54, 43.2 |
C33 | 29.0, 28.6 |
C34 | 24.2, 22.2 |
2θ | d(Å) | 상대강도 (>10%) |
5.56 | 15.8806 | 26.1 |
8.54 | 10.3456 | 100 |
10.96 | 8.0659 | 10.3 |
11.38 | 7.7694 | 36.0 |
14.32 | 6.1801 | 11.0 |
14.90 | 5.9408 | 11.5 |
18.18 | 4.8757 | 37.8 |
18.66 | 4.7513 | 29.3 |
19.04 | 4.6573 | 18.0 |
19.74 | 4.4938 | 20.0 |
22.38 | 3.9693 | 10.8 |
22.96 | 3.8703 | 14.9 |
탄소의 지정 | 화학적 이동 |
C12 또는 C25 | 183.3 |
C12 또는 C25 | 170.3 |
C16 | 164.0(광폭) |
방향족 탄소 C2-C5, C13-C18, C19-C24, C27-C32 |
138.1(광폭), 136.0, 131.7, 125.7, 121.8, 120.2 |
C8, C10 | 73.0 (광폭) |
메틸렌 탄소 C6, C7, C9, C11 |
44.3 (광폭) |
C33 | 29.1 |
C34 | 24.6 |
시료 | 융점(℃) |
실시예 1 | 231.9 |
실시예 2 | 191.7 |
실온 | |||
1개월 | 2개월 | 3개월 | 6개월 |
98.72 | 98.58 | 98.12 | 98.56 |
냉장 | |||
1개월 | 2개월 | 3개월 | 6개월 |
99.74 | 99.31 | 100.19 | 98.11 |
40℃/75% RH (가속) | 60℃/Dry (가혹) | ||
1개월 | 2개월 | 3개월 | 1개월 |
98.82 | 98.33 | 98.03 | 98.01 |
Claims (15)
- 제1항에 있어서, 약한(weak) 강도로 6.8, 10.8, 14.8, 16.2, 21.8, 25.1, 26.1, 27.2, 27.8, 28.5 및 30.4° 2θ에서 X선 분말 회절피크를 추가로 갖는 화학식 1화합물의 결정형 D1형 또는 이의 수화물.
- 제1항에 있어서, 약 179.6, 169.1, 162.5, 140.0, 138.0, 133.8, 131.9, 129.6, 126.0, 119.2, 114.7, 73.6, 71.2, 69.9, 48.0, 45.5, 43.2, 29.0, 28.6, 24.2 및 22.2 ppm에서 고체상태 13C NMR 신호를 나타내는 화학식 1화합물의 결정형 D1형 또는 이의 수화물.
- 제4항에 있어서, 약한(weak) 강도로 9.0 및 11.8(w)° 2θ 에서 X선 분말 회절피크를 추가로 갖는 화학식 1화합물의 결정형 D2형 또는 이의 수화물.
- 제4항에 있어서, 약 183.3, 170.3, 164.0(광폭), 138.1(광폭), 136.0, 131.7, 125.7, 121.8, 120.2, 73.0 (광폭), 44.3 (광폭), 29.1, 및 24.6 ppm에서 고체상태 13C NMR 신호를 나타내는 화학식 1화합물의 결정형 D2형 또는 이의 수화물.
- 제7항에 있어서, 알코올: 테트라하이드로퓨란: 물의 부피비가 1: 1: 8인 제조방법.
- 제9항에 있어서, 알코올: 메틸렌클로라이드: 물의 부피비가 10: 3: 30인 제조방법.
- 제7항 내지 제10항 중 어느 한 항에 있어서, 알코올은 탄소수 1내지 6인 저급 알코올인 제조방법.
- 제11항에 있어서, 알코올이 메탄올인 제조방법.
- 제1항 내지 제6항 중 어느 한 항의 결정형 또는 이의 수화물을 유효성분으로 함유하는 저밀도 지단백질(LDL)의 농도 저하용 약학적 조성물.
- 삭제
- 삭제
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08723256A EP2132171A4 (en) | 2007-03-02 | 2008-03-03 | NOVEL CRYSTALLINE FORMS OF PYRROLYLHEPTANOIC ACID DERIVATIVES |
RU2009136427/04A RU2421445C1 (ru) | 2007-03-02 | 2008-03-03 | Новые кристаллические формы производных пирролилгептановой кислоты |
US12/449,867 US7915302B2 (en) | 2007-03-02 | 2008-03-03 | Crystal forms of pyrrolylheptanoic acid derivatives |
PCT/KR2008/001218 WO2008108572A1 (en) | 2007-03-02 | 2008-03-03 | Novel crystal forms of pyrrolylheptanoic acid derivatives |
JP2009552583A JP2010520273A (ja) | 2007-03-02 | 2008-03-03 | ピロリルヘプタン酸誘導体の新規な結晶形態 |
CA002679317A CA2679317A1 (en) | 2007-03-02 | 2008-03-03 | Novel crystal forms of pyrrolylheptanoic acid derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20070020999 | 2007-03-02 | ||
KR1020070020999 | 2007-03-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080080959A KR20080080959A (ko) | 2008-09-05 |
KR101012917B1 true KR101012917B1 (ko) | 2011-02-08 |
Family
ID=40020978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080019764A KR101012917B1 (ko) | 2007-03-02 | 2008-03-03 | 피롤 헵탄산 화합물의 신규한 결정형 |
Country Status (8)
Country | Link |
---|---|
US (1) | US7915302B2 (ko) |
EP (1) | EP2132171A4 (ko) |
JP (1) | JP2010520273A (ko) |
KR (1) | KR101012917B1 (ko) |
CN (1) | CN101657419A (ko) |
CA (1) | CA2679317A1 (ko) |
RU (1) | RU2421445C1 (ko) |
WO (1) | WO2008108572A1 (ko) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011219437A (ja) * | 2010-04-14 | 2011-11-04 | Towa Yakuhin Kk | 結晶性形態tw−1のアトルバスタチンヘミカルシウム水和物とその製造方法 |
KR20120011249A (ko) * | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
RU2555360C2 (ru) * | 2012-11-06 | 2015-07-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ определения воды в координационных соединениях |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001036384A1 (en) * | 1999-11-17 | 2001-05-25 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
WO2002043732A1 (en) | 2000-11-30 | 2002-06-06 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
WO2003070702A1 (en) | 2002-02-15 | 2003-08-28 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
BR9609872A (pt) * | 1995-07-17 | 1999-03-23 | Warner Lambert Co | Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino |
US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
AP1571A (en) * | 2001-06-29 | 2006-02-10 | Warner Lambert Co | Crystalline forms of 'R-(R* ,R*)!-2-(4- fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1H-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
EP1562583A1 (en) * | 2002-09-03 | 2005-08-17 | Morepen Laboratories Ltd. | Atorvastatin calcium form vi or hydrates thereof |
CA2508871C (en) * | 2002-11-28 | 2008-09-09 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
WO2005090301A1 (en) * | 2004-03-17 | 2005-09-29 | Ranbaxy Laboratories Limited | Crystalline form of atorvastatin hemi calcium |
WO2006048894A1 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Novel crystalline forms of atorvastatin calcium and processes for preparing them. |
-
2008
- 2008-03-03 CN CN200880006877A patent/CN101657419A/zh active Pending
- 2008-03-03 US US12/449,867 patent/US7915302B2/en not_active Expired - Fee Related
- 2008-03-03 WO PCT/KR2008/001218 patent/WO2008108572A1/en active Application Filing
- 2008-03-03 RU RU2009136427/04A patent/RU2421445C1/ru not_active IP Right Cessation
- 2008-03-03 CA CA002679317A patent/CA2679317A1/en not_active Abandoned
- 2008-03-03 KR KR1020080019764A patent/KR101012917B1/ko active IP Right Grant
- 2008-03-03 EP EP08723256A patent/EP2132171A4/en not_active Withdrawn
- 2008-03-03 JP JP2009552583A patent/JP2010520273A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001036384A1 (en) * | 1999-11-17 | 2001-05-25 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
WO2002043732A1 (en) | 2000-11-30 | 2002-06-06 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
WO2003070702A1 (en) | 2002-02-15 | 2003-08-28 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix |
Also Published As
Publication number | Publication date |
---|---|
CN101657419A (zh) | 2010-02-24 |
WO2008108572A1 (en) | 2008-09-12 |
JP2010520273A (ja) | 2010-06-10 |
EP2132171A4 (en) | 2010-11-17 |
RU2009136427A (ru) | 2011-04-10 |
CA2679317A1 (en) | 2008-09-12 |
EP2132171A1 (en) | 2009-12-16 |
US20100113556A1 (en) | 2010-05-06 |
KR20080080959A (ko) | 2008-09-05 |
RU2421445C1 (ru) | 2011-06-20 |
US7915302B2 (en) | 2011-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100389518B1 (ko) | 결정질[r-(r*,r*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1h-피롤-1-헵탄산헤미칼슘염(아토르바스타틴) | |
BG108393A (bg) | Кристални форми на[r-(r*,r*)]-2-(флуорофенил)-бета, делта-дихидрокси-5-(1-метилетил)-3-фенил-4-[(фениламино)карбонил]-1н-пирол-1-хептанова киселина калциева сол (2:1) (аторвастатин) | |
AU2002255479B2 (en) | Crystalline forms VI and VII of atorvastatin clacium | |
JPH11509229A (ja) | 形態▲III▼の結晶性の(R−(R▲上*▼,R▲上*▼))−2−(4−フルオロフェニル)−β,δ−ジヒドロキシ−5−(1−メチル−エチル)−3−フェニル−4−((フェニルアミノ)カルボニル)−1H−ピロール−1−ヘプタン酸ヘミカルシウム塩(アトルバスタチン) | |
AU2002255479A1 (en) | Crystalline forms VI and VII of atorvastatin clacium | |
WO2005090301B1 (en) | Crystalline form of atorvastatin hemi calcium | |
KR101012917B1 (ko) | 피롤 헵탄산 화합물의 신규한 결정형 | |
US7074818B2 (en) | Crystalline forms VI and VII of Atorvastatin calcium | |
KR100878140B1 (ko) | 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물 | |
US10252993B2 (en) | Crystalline form of atorvastatin hemi-calcium salt, hydrate thereof, and method of producing the same | |
WO2006048894A1 (en) | Novel crystalline forms of atorvastatin calcium and processes for preparing them. | |
KR102013157B1 (ko) | 결정형 및 이의 제조방법 | |
JP2007505885A (ja) | [R−(R*,R*)]−2−(4−フルオロフェニル)−β,δ−ジヒドロキシ−5−(1−メチルエチル)−3−フェニル−4−[(フェニルアミノ)カルボニル]−1H−ピロール−1−ヘプタン酸の結晶性形態 | |
KR101723783B1 (ko) | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 | |
JPS61249970A (ja) | 新規な置換2−(n−アルキニル−n−フエニルアミノ)イミダゾリン誘導体 | |
KR920003604B1 (ko) | 1-(2,5-디플루오로페닐)-3-퀴놀린 카르본산 유도체 및 그 제조방법 | |
KR20110026831A (ko) | 신규 결정형의 아토바스타틴 칼슘염 또는 이의 수화물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20131226 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20141211 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20151230 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20161222 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20171219 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20191126 Year of fee payment: 10 |